Type I interferon inhibitor anifrolumab in active systemic lupus erythematosus (TULIP-1): a randomised, controlled, phase 3 trial

Authors: Richard Furie, Eric F. Morand, Ian N Bruce, Susan Manzi, Kenneth Kalunian, Edward M Vital, Theresa Lawrence Ford, Ramesh K. Gupta, Falk Hiepe, Mittermayer B. Santiago, Philip Z. Brohawn, Anna Berglind, Raj Tummala - The Lancet 2019 cited by 482